CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics to Participate in Upcoming Investor Conferences

01 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Third Quarter Results on November 2, 2023

23 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

06 Oct 2023 12:45:00 By Nasdaq GlobeNewswire

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

05 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

02 Oct 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

28 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

07 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Second Quarter 2023 Financial Results

03 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

01 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 3, 2023

27 Jul 2023 16:00:20 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

20 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

02 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

01 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

20 May 2023 10:30:56 By Nasdaq GlobeNewswire

Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress

15 May 2023 16:00:00 By Nasdaq GlobeNewswire